No Data
No Data
Visioneering Technologies Releases One-Year Data From Myopia Progression Control Study
Visioneering Technologies (ASX:VTI) said that full one-year results of its Progressive Myopia Treatment Evaluation for NaturalVue Multifocal Contact Lens Trial showed that 45% of subjects in the test
Visioneering Technologies Issues Part of Shortfall From Rights Offering
Visioneering Technologies (ASX:VTI) issued 1,084,843 CHESS depositary interests, forming part of the shortfall from its recent nonrenounceable rights offering. The shortfall securities were issued at
The top ten surging US stock ETFs are out! Tech stock ETFs soared by up to 430%, and “ETF benchmark” S&P SPY has absorbed US$50.5 billion
Judging from the US stock ETF growth list, ETFs that bet on cryptocurrencies, technology stocks, and the US property market have performed well.
Visioneering Technologies Raising Funds for Clinical Trial, Business Expansion
Visioneering Technologies (ASX:VTI) is looking to raise up to $2.6 million in funding from a rights offering and share placement, according to a Tuesday filing. The medical device company is targeting
Visioneering Technologies Appoints CEO
Visioneering Technologies (ASX:VTI) appointed Juan Carlos Aragón as its chief executive officer and executive director, effective Oct. 1, the US-based medical device company said Tuesday. Aragón has
No Data